» Articles » PMID: 32055888

Treatment of Ebola-related Critical Illness

Overview
Specialty Critical Care
Date 2020 Feb 15
PMID 32055888
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To explore contemporary clincial case management of patients with Ebola virus disease.

Methods: A narrative review from a clinical perspective of clinical features, diagnostic tests, treatments and outcomes of patients with Ebola virus disease.

Results: Substantial advances have been made in the care of patients with Ebola virus disease (EVD), precipitated by the unprecedented extent of the 2014-2016 outbreak. There has been improved point-of-care diagnostics, improved characterization of the clinical course of EVD, improved patient-optimized standards of care, evaluation of effective anti-Ebola therapies, administration of effective vaccines, and development of innovative Ebola treatment units. A better understanding of the Ebola virus disease clinical syndrome has led to the appreciation of a central role for critical care clinicians-over 50% of patients have life-threatening complications, including hypotension, severe electrolyte imbalance, acute kidney injury, metabolic acidosis and respiratory failure. Accordingly, patients often require critical care interventions such as monitoring of vital signs, intravenous fluid resuscitation, intravenous vasoactive medications, frequent diagnostic laboratory testing, renal replacement therapy, oxygen and occasionally mechanical ventilation.

Conclusion: With advanced training and adherence to infection prevention and control practices, clinical interventions, including critical care, are feasible and safe to perform in critically ill patients. With specific anti-Ebola medications, most patients can survive Ebola virus infection.

Citing Articles

Ebola outbreak in Guinea, 2021: Clinical care of patients with Ebola virus disease.

Pare B, Camara A, Camara A, Kourouma M, Enogo K, Camara M S Afr J Infect Dis. 2023; 38(1):454.

PMID: 36756241 PMC: 9900378. DOI: 10.4102/sajid.v38i1.454.


Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis.

Gao Y, Zhao Y, Guyatt G, Fowler R, Kojan R, Ge L Lancet Microbe. 2022; 3(9):e683-e692.

PMID: 35803293 PMC: 9441701. DOI: 10.1016/S2666-5247(22)00123-9.


Recent advances in carbon quantum dots for virus detection, as well as inhibition and treatment of viral infection.

Xue Y, Liu C, Andrews G, Wang J, Ge Y Nano Converg. 2022; 9(1):15.

PMID: 35366117 PMC: 8976173. DOI: 10.1186/s40580-022-00307-9.


COVID-19: Characteristics and Therapeutics.

Chilamakuri R, Agarwal S Cells. 2021; 10(2).

PMID: 33494237 PMC: 7909801. DOI: 10.3390/cells10020206.


[Intensive care back up for infectious disease disasters].

Wichmann D, Matthews H, Nentwich M, Schmiedel S, Kluge S Med Klin Intensivmed Notfmed. 2020; 115(8):641-648.

PMID: 33037459 PMC: 7546520. DOI: 10.1007/s00063-020-00743-7.

References
1.
Ilunga Kalenga O, Moeti M, Sparrow A, Nguyen V, Lucey D, Ghebreyesus T . The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018-2019. N Engl J Med. 2019; 381(4):373-383. DOI: 10.1056/NEJMsr1904253. View

2.
Rojek A, Horby P, Dunning J . Insights from clinical research completed during the west Africa Ebola virus disease epidemic. Lancet Infect Dis. 2017; 17(9):e280-e292. PMC: 5856335. DOI: 10.1016/S1473-3099(17)30234-7. View

3.
Chertow D, Kleine C, Edwards J, Scaini R, Giuliani R, Sprecher A . Ebola virus disease in West Africa--clinical manifestations and management. N Engl J Med. 2014; 371(22):2054-7. DOI: 10.1056/NEJMp1413084. View

4.
Beeching N, Fenech M, Houlihan C . Ebola virus disease. BMJ. 2014; 349:g7348. PMC: 4707720. DOI: 10.1136/bmj.g7348. View

5.
Kuhn J, Adachi T, Adhikari N, Arribas J, Bah I, Bausch D . New filovirus disease classification and nomenclature. Nat Rev Microbiol. 2019; 17(5):261-263. PMC: 6637750. DOI: 10.1038/s41579-019-0187-4. View